🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Premier Research 3️⃣ Reimbursement - No standardized payment model exists for commercial payers, however avenues are being explored. Tackling each of these areas requires a new approach, with technology undeniably playing a significant role. Read the full report ⬇️ cellandgene.com/doc/safety-eff…

10-12 October, 2023 Our team will be attending Alliance for Regenerative Medicine (ARM)'s Meeting at the Mesa where they'll discuss the cutting-edge research driving the future of #advancedtherapies. Catch us while you are here ➡️ meetingonthemesa.com

"It’s a fantastic feeling when we run a clinical trial that results in patients living longer." Dr. Yvonne Chen, an associate professor at UCLA, is a rising star of CAR-T #celltherapy for cancer treatment. Read about her research ➡️ stemcell.ucla.edu/news/member-sp…

A new report provides looks at how we can make cell & gene therapies more affordable & accessible. Key recommendations include the introduction of innovative #manufacturing methods & payment models to drive down costs for developers & payers. Read ➡️ bizjournals.com/bizwomen/news/…

We need #data to deliver better therapy products cheaper and faster… John Lee, Senior VP and Head of #CellTherapy at Center for Breakthrough Medicines, recently appeared on the Ori Spotlight #podcast to discuss the challenges and benefits of digitization. Listen here➡️open.spotify.com/episode/2S6HTM…

How do we get cell therapies to patients? ARM CEO Tim Hunt sits down with Jason Foster, CEO of Oribiotech, at ARM Studios today to outline his vision for launching a new platform technology to deliver these therapies to patients at scale. #CGMesa23

The first day of #CGMesa23 is in the books. We had a blast last night seeing our members at the Networking Bash. Thank you to everyone for making the first day a smashing success.

In partnership with Alliance for Regenerative Medicine (ARM), we are bringing together leaders immediately after close of this year's #CGMesa23 to workshop the importance of digital in CGT. We’ll explore the urgent need to move beyond the #digital status quo to improve patient access to #advancedtherapies.

Fresh from our Digital workshop at #CGMesa23... We're throwing it back to Alliance for Regenerative Medicine (ARM) CEO Tim Hunt on the #OriSpotlight podcast, exploring the importance of digital-first solutions that create scalability, flexibility & connectivity across manufacturing➡️open.spotify.com/episode/3tSyNv…

Earlier this month, we attended Alliance for Regenerative Medicine (ARM)'s Meeting on Mesa The team had a jam-packed agenda connecting with others in the industry, including: 🔷Over 70 meetings 🔷Sharing our preliminary biology data for the first time 🔷Holding our #digital workshop in partnership with ARM

How can we bring #Industry40 to pharma #manufacturing? Our CEO Jason C. Foster recently joined The Medicine Maker's Industry 4.0 round table discussion, topics included: 🔷 Simplifiying processes through digitization 🔷Identifying how and when to scale up ➡️themedicinemaker.com/manufacture/ad…

With nearly 30% of approved gene therapies removed from the market in Europe for commercial reasons, CEO Jason C. Foster explains why manufacturing could be the fix ⬇️ cellandgene.com/doc/the-new-ec…

After several rounds of unsuccessful treatments for large diffuse B-cell lymphoma, Madam Fung Mei Fong was close to giving up… But 1 year after CAR-T #celltherapy, she is in remission. Read her story in The Straits Times ➡️ straitstimes.com/singapore/heal…

🦠Columbia University researchers have developed a new approach to find & destroy solid tumors: 1️⃣ Probiotic bacteria seek out solid tumors & "tag" the tumor with a synthetic CAR target 2️⃣ CAR-T cells home in and kill these CAR tagged tumors Read more ➡️ genengnews.com/topics/cancer/…

At Cell&Gene's Meeting on the Mesa conference, Jason C. Foster shared our primary scientific data publicly for the very first time. See the highlights ⬇️ 📹 To delve deeper into our breakthroughs and vision, watch the presentation on YouTube: youtube.com/watch?v=HRHcUS…

We’re taking a moment to reflect on the pivotal milestones we’ve achieved this year…beginning with our scientific data. Here's a glimpse of our progress this year⬇️ 📹Watch Jason C. Foster's presentation: youtube.com/watch?v=HRHcUS…

2023 was an inflection point for the cell and #genetherapy industry, shifting from traditional paper-based #manufacturing processes to embracing the need for #Digital transformation… Here are some of our favorite #digital stories of 2023 ⬇️

We're kicking off an exciting 2024 with Phacilitate's #AdvancedTherapies Week in Miami! 🌴 Thomas Heathman, Maria O'Callaghan and Kale Feeter will be representing Ori – don't miss Maria's roundtable on Jan 16th! Drop us a message to arrange a meeting ⬇️

A newly identified CAR-T #celltherapy target, GRP78, could be key to treating solid tumors. 🦠 This could be a game-changer for patients with brain and solid tumors. 🔍 Learn more: technologynetworks.com/biopharma/news…

🎙️ Accenture US's Sanjay Srivastava recently joined Jason C. Foster to discuss the struggle of scaling up whilst maintaining business viability. Find out why he thinks thinking about #manufacturing early will help solve the scalability challenge... 📺 youtu.be/kdnYJKZRYCA